Uncategorized
Biotime Expands & Advances Ophthalmology Portfolio
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today reported several developments for its ophthalmology portfolio including: Signing a new and expanded licensing agreement with Hadassah Medical Organization of Jerusalem, Israel Presentation of data from its Phase 1/2a Dose Escalation Study of OpRegen® at ISSCR Presentation of the similarities between human retinal